Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and Tonix will assume that license.
Trigemina Chief Medical Officer Shashidar H. Kori said, “We are excited that Tonix will continue to advance the progress Trigemina has made with these assets and look forward to potentially facilitating their development. This agreement further validates our previous development work and its continued potential.”
Tonix President and CEO Seth Lederman commented, “Tonix is excited to develop intranasal oxytocin as a non-addictive treatment for migraine and craniofacial pain. The preclinical data that we have seen to date are promising and show that oxytocin, a natural hormone, is capable of blocking the release of the neurotransmitter calcitonin gene-related peptide (CGRP) in the brain coverings and trigeminal ganglia, thus potentially preventing a key step in the causation of migraine. It has been shown that intra-nasally delivered oxytocin selectively reaches the trigeminal ganglia with low systemic absorption. Overall, we believe that TNX-1900 has the potential to be a safe, natural, non-addicting, non-constipating and easy to administer alternative to opioids to treat migraine and craniofacial pain.”
Read the Tonix Pharmaceuticals press release.
